COVID-19

Pharma Courses 
PAGE Admission

  • Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

  • 19 May 2020
    Recruitment for Pharmacists (12 posts) at S.C.B. Medical College & Hospital

    The origin of the dispensary which the Cuttack general hospital replaced, is lost in antiquity. It is believed to have existed since the days of Indian Rule in Orissa and was established primarily for the benefit of the pilgrims proceedings to Puri (otherwise called Jagannath). It was originally maintained from the proceeds of an endowment made by Marahatta Government.

    Post : Pharmacist

  • 19 May 2020
    Vacancy for Technical Officer at NIRRH | Salary Rs. 45,000/- p.m

    National Institute for Research in Reproductive Health (NIRRH), formerly known as Institute for Research in Reproduction is a premier research institute of the Indian Council of Medical Research (ICMR). It is situated in the vicinity of a number of hospitals and research institutes in central Mumbai. Since its inception in 1970, it has been making vigorous efforts to improve the reproductive health of people through research, education and health care services.

    Post : Technical Officer

  • 17 May 2020
    Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications

    COVID-19 can cause serious cardiovascular complications including heart failure, heart attacks and blood clots that can lead to strokes, emergency medicine doctors report in a new scientific paper. They also caution that COVID-19 treatments can interact with medicines used to manage patients' existing cardiovascular conditions.

  • 17 May 2020
    US based Sorrento Therapeutics claims breakthrough against COVID-19, shares jumps around 244 percent

    San Diego based Sorrento Therapeutics claims that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration which lead to jumps in stocks around 244%.

  • 16 May 2020
    Antiviral drug can speed up recovery of COVID-19 patient : Research

    An international team of researchers led by Dr. Eleanor Fish, emerita scientist at the Toronto General Hospital Research Institute, University Health Network, and professor in the University of Toronto's Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.

  • The Council of Scientific and Industrial Research (CSIR), through its New Millennium Indian Technology Leadership Initiative (NMITLI) program, has approved a project towards development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team.

  • Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic.

  • COVID-19, the disease caused by coronavirus SARS-Cov-2, has infected over 4 million people in 212 countries, of whom at least 272,000 have died. The ongoing economic and social impact of the pandemic is staggering, but despite a daily flood of news on the disease, few laypeople know that paradoxically, COVID-19 mostly kills through an overreaction of the immune system, whose function is precisely to fight infections.

  • U.S. Food and Drug Administration authorized the first diagnostic test with the option of using home-collected saliva samples for COVID-19 testing. Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular-based LDT “umbrella” EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device. This announcement builds on last month’s EUA for the first diagnostic test with a home-collection option, which uses a sample collected from the patient’s nose with a nasal swab and saline.

Subscribe to COVID-19